Sign In
Buy SLRX
$0.84
+0 (+0%)
At Close: Apr 14, 2026
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results
04:05pm, Thursday, 18'th Mar 2021
Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET
Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results
04:15pm, Thursday, 11'th Mar 2021
Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET
HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric can
Salarius Announces Proposed Public Offering of Common Stock
04:05pm, Wednesday, 03'rd Mar 2021
HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric can
SLRX Stock Price Increases Over 20% Pre-Market: Why It Happened
08:25am, Wednesday, 24'th Feb 2021
The stock price of Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is trading at over 20% pre-market. This is why it happened.
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference
07:30am, Monday, 22'nd Feb 2021
HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
Seclidemstat safety profile affirmed; Recommended Phase 2 dose established
Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference
07:30am, Tuesday, 16'th Feb 2021
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumor
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
08:05am, Thursday, 21'st Jan 2021
HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric can
Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas
07:30am, Wednesday, 13'th Jan 2021
HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
Salarius Pharmaceuticals to Participate in Biotech Showcase Digital and BIO @ JPM During "J.P. Morgan Week 2021"
07:30am, Tuesday, 22'nd Dec 2020
HOUSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumor
Salarius Announces Exercise Of Warrants For $3.5 Million Of Gross Proceeds To Be Used For Ongoing Development Of Seclidemstat
11:32am, Friday, 11'th Dec 2020
HOUSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric canc
Salarius Pharmaceuticals to Participate in A.G.P.'s Virtual Healthcare Symposium
07:30am, Tuesday, 17'th Nov 2020
HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric can
